Viktoria Bergqvist
1 – 6 of 6
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
2024) In Digestive Diseases and Sciences(
- Contribution to journal › Article
- 2022
-
Mark
Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply
2022) In Alimentary Pharmacology and Therapeutics(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease
(
- Contribution to journal › Article
-
Mark
Letter: to switch or not to switch, that is the question—author's reply
(
- Contribution to journal › Letter
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2017
-
Mark
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
(
- Contribution to journal › Article